Eureka-AI is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Eureka AI

1701 results about "Lung cancer" patented technology

Cancer which begins in the cells of the lung.

Method and system for grading and managing detection of pulmonary nodes based on in-depth learning

ActiveCN107103187AAutomatic nodule grading managementAutomatic diagnosisCharacter and pattern recognitionMedical automated diagnosisMedicineLow-Dose Spiral CT
The invention discloses a method for grading and managing detection of pulmonary nodes based on in-depth learning. The method for grading and managing detection of the pulmonary nodes based on in-depth learning is characterized by comprising the steps of S100, collecting a chest ultralow-dose-spiral CT thin slice image, sketching a lung area in the CT image, and labeling all pulmonary nodes in the lung area; S200, training a lung area segmentation network, a suspected pulmonary node detection network and a pulmonary node sifting grading network; S300, obtaining pulmonary node temporal sequences of all patients in an image set and grading information marks corresponding to the pulmonary node sequences to construct a pulmonary node management database; S400, training a lung cancer diagnosis network based on a three-dimensional convolutional neural network and a long-short-term memory network. According to the method for grading and managing detection of the pulmonary nodes based on in-depth learning, the lung area segmentation network, the suspected pulmonary node detection network, the pulmonary node sifting grading network and the lung cancer diagnosis network are trained based on in-depth learning, the pulmonary nodes are accurately detected, and through the combination of subsequent tracking and visiting, more accurate diagnosis information and clinic strategies are obtained.

Traditional Chinese medicine preparation for treating cancer and preparation method thereof

The invention discloses a traditional Chinese medicine preparation for treating cancer, which is prepared by 103 types of bulk drugs such as solidago decurrens, Chinese sage herb, hypericum japonicumand the like. A preparation method of the traditional Chinese medicine preparation comprises the following steps: preparing the bulk drugs into water extract by a conventional method; using the prepared water extract for preparing oral solution by a traditional method; drying the obtained water extraction, then conducting grinding and sieving; taking the throughs for extracting powder, and using the extracted powder for preparing tablets, granules, electuaries or capsules by a traditional method. The preparation method also can be as follows: sieving out the dust of the bulk drugs, conductinggrinding and sieving, taking the throughs, conducting disinfection and sterilization to obtain raw powder, and using the raw powder for preparing tablets, granules, electuaries or capsules by a traditional method. With drugs mixed rationally, the traditional Chinese medicine preparation addresses both the symptoms and root causes of cancer. The bulk drugs are frequently-used common Chinese drugs,have low preparation cost and small side effect, and can effectively enhance own immunity, attack pathogen while do not damage body. The traditional Chinese medicine preparation can cure various typesof cancer, particularly lung cancer, stomach cancer, liver cancer, esophageal cancer, pancreatic cancer, cervical cancer and breast cancer.

Novel compounds as rearranged during transfection (RET) inhibitors

ActiveUS20170298074A1Organic active ingredientsOrganic chemistry methodsDiseaseFunctional diarrhea
This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products